在慢性阻塞性肺病患者中,支气管扩展剂可逆性和eosinophilic生物标志物
H Ameet1, Deependra K Rai2, Saurabh Karmakar2
1Department of Respiratory Medicine, Malla Reddy Institute of Medical Sciences, Hyderabad, Telangana, India.
Lung India : official organ of Indian Chest Society
|February 27, 2025
概括
在慢性阻塞性肺病 (COPD) 中,乙素生物标志物在具有支气管扩展剂可逆性的患者中显著更高. 在这种COPD子组中,液中乙氨基酸水平显示出比外围乙氨基酸水平更强的相关性.
科学领域:
- 肺部病理学 肺部病理学
- 呼吸系统医学 呼吸系统医学
- 炎症研究 炎症研究
背景情况:
- 慢性阻塞性肺病 (COPD) 是全球主要的死亡原因之一.
- 一个COPD患者的子组表现出eosinophilic炎症和类似喘的特征.
- 了解支气管扩展剂的可逆性和eosinophilic标志物对于COPD管理至关重要.
研究的目的:
- 为了确定COPD患者中支气管扩展剂可逆性的比例.
- 为了比较可逆性和不可逆性COPD组之间的eosinophilic生物标志物.
- 调查乙酸蛋白在具有可逆性特征的慢性肺炎中所扮演的角色.
主要方法:
- 一项针对160名COPD患者的医院横截面研究.
- 进行了螺旋计,以评估支气管扩展剂的可逆性.
- 测量了包括血中乙酸氨基,唾液中的乙酸氨基,FeNO和血清IL-5在内的乙酸氨基生物标志物.
主要成果:
- 在COPD队列中,支气管扩展剂可逆性的患病率为32%.
- 在可逆性和不可逆性组之间观察到唾液中乙氨基酸计数,外围乙氨基酸计数和FeNO水平的显著差异.
- 在GOLD组D患者中,血清IL-5水平显著更高.
结论:
- 乙氨基酸在COPD患者的炎症反应中发挥着重要作用,这些患者具有支气管扩展剂可逆性.
- 升高的乙素生物标志物是这种COPD亚组的特征.
- 唾液中乙氨基酸水平与外围乙氨基酸水平相比显示出更好的相关性.
相关概念视频
01:26COPD: Management Using Bronchodilators and Corticosteroids
170
Chronic obstructive pulmonary isease (COPD) involves a group of progressive lung disorders characterized by persistent airflow limitation and chronic respiratory symptoms. Asthma-COPD Overlap Syndrome (ACOS), encompassing features of both asthma and Chronic obstructive pulmonary disease (COPD), is a group of progressive lung disorders that includes chronic bronchitis, emphysema, and refractory (non-reversible) asthma. ACOS leads to complex clinical presentations that combine the inflammatory...
170
01:20Chronic Obstructive Pulmonary Disease-II: Pathophysiology
2.7K
Chronic Obstructive Pulmonary Disease (COPD) pathophysiology is intricate and multifaceted, involving a complex interplay of physiological processes. Understanding these mechanisms is crucial for effectively managing and treating COPD. Here is an in-depth look at the critical elements in the pathophysiology of COPD:
Chronic Inflammation
Chronic Inflammation
2.7K
01:27Chronic Obstructive Pulmonary Disease-IV: Assessement and Diagnostic Studies
2.5K
Assessing and diagnosing Chronic Obstructive Pulmonary Disease (COPD) involves a detailed approach that includes a comprehensive review of medical history, physical examination, and a variety of diagnostic tests. This thorough evaluation is essential to ensure an accurate diagnosis and guide effective management strategies.
Medical History
Medical History
2.5K
01:22Chronic Obstructive Pulmonary Disease
1.1K
COPD is defined as a heterogeneous lung condition marked by persistent respiratory symptoms such as dyspnea, cough, and sputum production, caused by abnormalities in the airways that cause airflow obstruction.
Smoking is a primary risk factor for COPD, with over 80% of patients having a history of it. Patients typically experience progressive dyspnea or labored breathing, frequent coughing, and recurrent pulmonary infections. Many eventually succumb to respiratory failure, characterized by...
Smoking is a primary risk factor for COPD, with over 80% of patients having a history of it. Patients typically experience progressive dyspnea or labored breathing, frequent coughing, and recurrent pulmonary infections. Many eventually succumb to respiratory failure, characterized by...
1.1K
01:20Chronic Obstructive Pulmonary Disease-I: Introduction
2.7K
Chronic Obstructive Pulmonary Disease (COPD) is a long-lasting respiratory condition requiring continuous attention and care. It is a progressive lung disease that leads to breathing challenges due to airflow obstruction. It manifests as persistent respiratory symptoms and restricted airflow resulting from abnormalities in the airways and alveoli, usually due to long-term exposure to harmful particles or gases. COPD mainly consists of two primary conditions: emphysema and chronic bronchitis.
2.7K
01:17Drugs Used in Lower Respiratory Disorders: Overview
334
Lower respiratory tract disorders present challenges that often require skilled and nuanced approaches for effective management. Common ailments, such as asthma and chronic obstructive pulmonary disease (COPD), have prompted the development of intricate treatment strategies involving bronchodilators and anti-inflammatory drugs, each tailored to ease breathing and revitalize the lungs.
Bronchodilators, the first step of respiration enhancement, come in various forms, each with its own mechanism...
Bronchodilators, the first step of respiration enhancement, come in various forms, each with its own mechanism...
334